美国食品和药物管理局的指导草案支持MRD作为多发性骨髓瘤试验的标准措施. FDA draft guidance endorses MRD as standard measure for multiple myeloma trials.

血液癌症联合,ASH和GSK以及约翰逊与约翰逊等主要制药公司公开支持FDA的指导草案,支持将最小残留疾病作为多发性骨髓瘤试验标准措施. Blood Cancer United, ASH, and major drugmakers like GSK and Johnson & Johnson have publicly endorsed the FDA’s draft guidance supporting the use of minimal residual disease as a standard measure for multiple myeloma trials. 这些提交的内容旨在加速新疗法开发,并提高治疗有效性评估的准确度. These submissions aim to accelerate the development of new therapies and improve the accuracy of treatment effectiveness evaluations.